U.S. flag

An official website of the United States government

NM_001201543.2(FAM161A):c.1153C>G (p.Gln385Glu) AND not provided

Germline classification:
Conflicting interpretations of pathogenicity (4 submissions)
Last evaluated:
Apr 1, 2024
Review status:
criteria provided, conflicting classifications
Somatic classification
of clinical impact:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Somatic classification
of oncogenicity:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Record status:
current
Accession:
RCV000416124.35

Allele description [Variation Report for NM_001201543.2(FAM161A):c.1153C>G (p.Gln385Glu)]

NM_001201543.2(FAM161A):c.1153C>G (p.Gln385Glu)

Gene:
FAM161A:FAM161 centrosomal protein A [Gene - OMIM - HGNC]
Variant type:
single nucleotide variant
Cytogenetic location:
2p15
Genomic location:
Preferred name:
NM_001201543.2(FAM161A):c.1153C>G (p.Gln385Glu)
HGVS:
  • NC_000002.12:g.61839851G>C
  • NG_028125.1:g.19293C>G
  • NM_001201543.2:c.1153C>GMANE SELECT
  • NM_032180.3:c.1153C>G
  • NP_001188472.1:p.Gln385Glu
  • NP_115556.2:p.Gln385Glu
  • NC_000002.11:g.62066986G>C
  • NM_001201543.1:c.1153C>G
  • NM_032180.2:c.1153C>G
  • NR_037710.2:n.1116C>G
Protein change:
Q385E
Links:
dbSNP: rs139266382
NCBI 1000 Genomes Browser:
rs139266382
Molecular consequence:
  • NM_001201543.2:c.1153C>G - missense variant - [Sequence Ontology: SO:0001583]
  • NM_032180.3:c.1153C>G - missense variant - [Sequence Ontology: SO:0001583]
  • NR_037710.2:n.1116C>G - non-coding transcript variant - [Sequence Ontology: SO:0001619]
Observations:
5

Condition(s)

Synonyms:
none provided
Identifiers:
MedGen: C3661900

Recent activity

Assertion and evidence details

Submission AccessionSubmitterReview Status
(Assertion method)
Clinical Significance
(Last evaluated)
OriginMethodCitations
SCV000114246Eurofins Ntd Llc (ga)
criteria provided, single submitter

(EGL Classification Definitions 2015)
Uncertain significance
(Aug 16, 2013)
germlineclinical testing

Citation Link,

SCV000493669CeGaT Center for Human Genetics Tuebingen
criteria provided, single submitter

(CeGaT Center For Human Genetics Tuebingen Variant Classification Criteria Version 2)
Likely benign
(Apr 1, 2024)
germlineclinical testing

Citation Link,

SCV001109025Labcorp Genetics (formerly Invitae), Labcorp
criteria provided, single submitter

(Invitae Variant Classification Sherloc (09022015))
Benign
(Jan 31, 2024)
germlineclinical testing

PubMed (1)
[See all records that cite this PMID]

SCV001551851Department of Pathology and Laboratory Medicine, Sinai Health System - The Canadian Open Genetics Repository (COGR)

See additional submitters

no assertion criteria provided
Likely benignunknownclinical testing

Summary from all submissions

EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
not providedgermlineyes2not providednot providednot providednot providedclinical testing
not providedgermlineunknown3not providednot providednot providednot providedclinical testing
not providedunknownyesnot providednot providednot providednot providednot providedclinical testing

Citations

PubMed

Sherloc: a comprehensive refinement of the ACMG-AMP variant classification criteria.

Nykamp K, Anderson M, Powers M, Garcia J, Herrera B, Ho YY, Kobayashi Y, Patil N, Thusberg J, Westbrook M; Invitae Clinical Genomics Group., Topper S.

Genet Med. 2017 Oct;19(10):1105-1117. doi: 10.1038/gim.2017.37. Epub 2017 May 11. Erratum in: Genet Med. 2020 Jan;22(1):240. doi: 10.1038/s41436-019-0624-9.

PubMed [citation]
PMID:
28492532
PMCID:
PMC5632818

Details of each submission

From Eurofins Ntd Llc (ga), SCV000114246.8

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not provided3not providednot providedclinical testingnot provided
#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot provided3not providednot providednot provided

From CeGaT Center for Human Genetics Tuebingen, SCV000493669.15

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not provided2not providednot providedclinical testingnot provided

Description

FAM161A: BP4, BS2

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineyesnot providednot providednot provided2not providednot providednot provided

From Labcorp Genetics (formerly Invitae), Labcorp, SCV001109025.6

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testing PubMed (1)
#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided

From Department of Pathology and Laboratory Medicine, Sinai Health System - The Canadian Open Genetics Repository (COGR), SCV001551851.1

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testingnot provided

Description

The FAM161A p.Gln385Glu variant was identified in 1/273 unrelated patients with retinitis pigmentosa (freq=0.002) and 2/270 healthy controls (freq=0.004) (Venturini_2014_PMID: 24651477). There are also no pathogenic missense variants in FAM161A reported in ClinVar. The variant was also identified in dbSNP (ID: rs139266382), LOVD 3.0 (reported as likely benign) and ClinVar (classified as a variant of uncertain significance by EGL Genetic Diagnostics and Praxis fuer Humangenetik Tuebingen). The variant was not identified in Cosmic. The variant was identified in control databases in 945 of 279988 chromosomes (5 homozygous) at a frequency of 0.003375 increasing the likelihood this could be a low frequency benign variant (Genome Aggregation Database Feb 27, 2017). The variant was observed in the following populations: European (non-Finnish) in 785 of 127800 chromosomes (freq: 0.006142), Other in 17 of 7126 chromosomes (freq: 0.002386), European (Finnish) in 59 of 25038 chromosomes (freq: 0.002356), African in 26 of 24182 chromosomes (freq: 0.001075), South Asian in 25 of 30600 chromosomes (freq: 0.000817), Latino in 28 of 35366 chromosomes (freq: 0.000792) and Ashkenazi Jewish in 5 of 10342 chromosomes (freq: 0.000484); it was not observed in the East Asian population. The variant occurs outside of the splicing consensus sequence and in silico or computational prediction software programs (SpliceSiteFinder, MaxEntScan, NNSPLICE, and GeneSplicer) do not predict a difference in splicing. The p.Gln385 residue is not conserved in mammals and four out of five computational analyses (SIFT, AlignGVGD, BLOSUM, and MutationTaster) do not suggest a high likelihood of impact to the protein; however, this information is not predictive enough to rule out pathogenicity. In summary, based on the above information the clinical significance of this variant cannot be determined with certainty at this time although we would lean towards a more benign role for this variant. This variant is classified as likely benign.

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1unknownyesnot providednot providednot providednot providednot providednot providednot provided

Last Updated: Nov 10, 2024